About Somatuline^® Depot (lanreotide) Injection

Somatuline Depot is a medical treatment for acromegaly that's different from other treatments.

It's FDA-approved as an effective, safe, and generally well-tolerated medication for treating acromegaly. Find out more about what Somatuline Depot is.

Acromegaly is a rare condition that affects three to four out of every million people per year. Somatuline Depot has helped people with acromegaly; last year over 6000 people took it for acromegaly. See who should take it.

Somatuline Depot helps your body control acromegaly by mimicking a natural hormone. Learn more about how it works.

Only Somatuline Depot comes in a ready-to-use, prefilled syringe and has a simple, easy injection procedure. Watch a short video and read about how to take Somatuline Depot.

The effects of Somatuline Depot last as long as you are on therapy. Find out about how long to take Somatuline Depot.

Possible side effects of Somatuline Depot

Like all other medications, Somatuline Depot can cause side effects. Learn about possible side effects of Somatuline Depot.

Resources for those who take Somatuline Depot

While it is not a common condition, there are many people with acromegaly. Look into support groups and resources for people who take Somatuline Depot.

Could Somatuline Depot help you?

Last year Somatuline Depot helped over 6000 people with acromegaly, including three functional, but typical, patients named Dave, Mark, and Karen. See if you're like Dave, or Mark, or Karen.

IMPORTANT SAFETY INFORMATION

Somatuline^® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline^® Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

SOMATULINE^® DEPOT IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).

2008 Tercica Legal Notices | Privacy Statement